Cargando…
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
The treatment options for metastatic non-small-cell lung cancer (NSCLC) have expanded dramatically in the last 10 years with the discovery of newer drugs and targeted therapy. Epidermal growth factor receptor (EGFR), when aberrantly activated, promotes cell growth and contributes in various ways to...
Autores principales: | Thakur, Manish K, Wozniak, Antoinette J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342611/ https://www.ncbi.nlm.nih.gov/pubmed/28293124 http://dx.doi.org/10.2147/LCTT.S104207 |
Ejemplares similares
-
Clinical potential of necitumumab in non-small cell lung carcinoma
por: Genova, Carlo, et al.
Publicado: (2016) -
Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients
por: Chigutsa, E, et al.
Publicado: (2017) -
Population Pharmacokinetics of Necitumumab in Cancer Patients
por: Long, Amanda, et al.
Publicado: (2016) -
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives
por: Bly, Christopher A., et al.
Publicado: (2018) -
Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
por: Weart, Thomas C, et al.
Publicado: (2018)